Watching Protagenic Therapeutics, Inc.\new? See every signal: funding, hires, M&A, contracts, sentiment.
Book a demoChoose your planProtagenic Therapeutics, Inc.\new
AI Executive Summary
AI-powered analysis of 10-K filing content
Protagenic is a clinical-stage biopharmaceutical company with no approved products or revenue, facing a going concern issue with cash sufficient only until the end of Q3 2026. The company recently unwound a reverse merger with Phytanix Bio amid litigation (now settled), which severely complicates financial comparability and reflects governance turmoil. Internal controls over financial reporting were deemed ineffective, citing material weaknesses including lack of segregation of duties concentrated in the Executive Chairman.
Red Flags Detected (7)
Going concern doubt explicitly disclosed; cash runway only through Q3 2026
Internal control over financial reporting deemed not effective due to material weaknesses
Heavy reliance on Executive Chairman for nearly all key financial duties with access to all financial information
4 more red flags detected
Key Takeaways
Company is a clinical-stage biopharma with lead candidate PT00114 (TCAP-1) still in Phase 1, with Phase 2 not expected until late 2026
No revenue-generating products; entirely dependent on external financing to continue operations
3 more takeaways
Filing Overview
What This Means
High Risk Filing: This company is showing signs of financial stress or significant operational challenges.
Deteriorating Trend: Conditions are worsening compared to previous filings. This may create opportunities for service providers.
Annual Report: Comprehensive filing covering the full fiscal year with audited financial statements.